Boy aged 5 caught on camera stealing mobile phone from charity shop assistant – Mirror Online #cctv,scotland #yard,cancer #research #uk,crime,metropolitan #police


Boy aged 5 caught on camera ‘stealing mobile phone from charity shop assistant’

A boy believed to be just five years old was enlisted by two men to steal from a Cancer Research store in a distraction theft.

Police are hunting the duo who distracted staff as the little lad nabbed the assistant’s phone – clothing was also pilfered from the fundraising shop.

Scotland Yard released CCTV footage of one of the men instructing the boy to take the phone behind the till of the store in Wimbledon, south-west London. The other man is said to have been distracting staff.

The boy is then seen lifting up his top and stuffing the phone down the front of his trousers.

Police in south-west London are appealing for the public’s help after two men used a young boy, believed to be aged five, as part of a distraction theft at a charity shop (Photo: Met Police)

The men, who detectives wish to trace, then left the store with the shop assistant’s phone and with women’s clothing which they did not pay for, the Metropolitan Police said.

Officers were called at around 3.45pm on October 11 to the store in High Street to reports of the theft.

Police described the first suspect as a large white man in his early 30s with a brown beard, while the second was a large white man in his late 20s.

Detectives want to speak to both men captured on CCTV in a south-west London charity shop in connection with a distraction theft (Photo: Met Police)

Officers believe the boy is aged around five and they said he is white with short brown hair.

Pc Sue Clarke said: We are keen to identify the two men in the CCTV footage who appear to use the child in their care to steal from those working in a Cancer Research shop.

A member of staff’s phone and women’s clothing were taken from the Cancer Research store in High Street, Wimbledon (Photo: Met Police)

We would also urge anyone who witnessed the incident to contact us.

Anyone with information should call police on 101 or Crimestoppers anonymously on 0800 555 111.

Causes of Mesothelioma – Malignant Mesothelioma Information #causes #of #mesothelioma, #malignant #mesothelioma #asbestos #asbestosis #cancer

Causes of Mesothelioma

Asbestos exposure is one of the most common causes of mesothelioma. Over 50 percent of mesothelioma patients have a history of asbestos exposure. This exposure could occur while directly handling the fibrous material, or it could occur through just environmental exposure.

There are numerous documented cases where patients contracted the disease due to living close to the asbestos mines or by coming in contact with asbestos when some of the fibers became airborne. Persons most commonly afflicted include shipyard workers, construction workers, automobile mechanics (particularly those working on brake linings), insulation workers, pipe and heater installation and flooring workers and roofers.

Also, for those who have had asbestos exposure and who smoke, the risk becomes exaggerated. Studies show that asbestos workers who also smoke are 55 times more likely to die of mesothelioma than nonsmokers without asbestos exposure.


Erionite is a mineral that has a long, thin rod-like amphiboles structure. Exposure to this mineral has been associated with increased incidence of mesothelioma. Many cases of mesothelioma due to erionite exposure have been diagnosed in the Central Anatolia region of Turkey.

Exposure to asbestos is the primary cause for malignant mesothelioma in most patients. If you or a loved one has been exposed to asbestos, then you are at risk. There is no minimum level of exposure that is deemed safe. Insure that during your routine health care, you advise your doctor of previous asbestos exposure, particularly if you experience any chest pressure, shortness of breath, chest pain or coughing. While these symptoms do not indicate the presence of the disease, they are the most common symptoms and should be further investigated if you have had asbestos exposure.

[Page updated February 2005]

Serving Clients Throughout California
Call Today

ATTORNEY ADVERTISEMENT Thank you for your visit. This website was created to provide persons affected by mesothelioma with current, up-to-date information. The content published on this website was not written by medical professionals and should not, at any point, be mistaken for medical advice. Furthermore, the information on this site is intended for educational purposes only and should never interfere with a patient/site visitor and his or her healthcare provider. In addition, viewing the content on this website, requesting additional information, or transmitting information through a contact form should never be considered the formation of an attorney-client relationship. The material published on this site is general and may not apply to your specific circumstances. Every case comes with its own set of unique circumstances; past success discussed on this site does not guarantee future performance. Information found on this website should not be used as incentive to act without seeking counsel from a professional.

All About Malignant Mesothelioma: Your Mesothelioma Information Source
2005-2015 Ceatus Media Group LLC
Copying or reproducing any text or graphics from this website is strictly prohibited by copyright law.

Treatment of Metastatic Castration-Resistant Prostate Cancer #information #on #prostate #cancer #and #treatment


September 8, 2014

To help doctors give their patients the best possible care, the American Society of Clinical Oncology (ASCO), along with Cancer Care Ontario, has developed recommendations on systemic, or full-body, treatments for men with metastatic castration-resistant prostate cancer. This guide for patients and caregivers is based on ASCO recommendations.

  • Metastatic castration-resistant prostate cancer is when the cancer has spread to parts of the body other than the prostate, and it is able to grow and spread even though drugs or other treatments to lower the amount of male sex hormones are being used to manage the cancer.
  • When deciding on treatments for metastatic castration-resistant prostate cancer, it is important to weigh the possible benefits with the risks and costs.
  • There are several different treatment options available for this type of prostate cancer.
  • In addition to treatment for the cancer, relieving symptoms and side effects is an important part of cancer care and treatment.

Prostate cancer growth is often driven by male sex hormones called androgens, which include testosterone. Because of this, a common treatment option for prostate cancer is to lower the levels of androgens in a man’s body. Androgen levels can be lowered by surgically removing the testicles or with drugs that stop the testicles from making androgens or block how they affect the body. This type of treatment is called hormone therapy or androgen-deprivation therapy.

If the cancer spreads to other parts of the body beyond the prostate in a process called metastasis, hormone therapy is usually continued. Eventually, many men with metastatic prostate cancer develop castration-resistant disease. This means that the cancer is able to grow and continue to spread despite using hormone therapy. For men with this type of disease, additional treatment is needed to help control the growth of the cancer. These treatments may include chemotherapy. targeted therapy. and other types of treatments.

Recommendations for men with metastatic castration-resistant prostate cancer

ASCO recommends that men with metastatic castration-resistant prostate cancer continue hormone therapy to keep androgen levels in the body low, regardless of the other treatments used. Relieving side effects, also called symptom management or palliative care. is also an important part of cancer care and treatment.

The following treatments may be given in addition to continuing hormone therapy:

  • Abiraterone (Zytiga) and prednisone (multiple brand names)
  • Enzalutamide (Xtandi)
  • Radium-223 (Xofigo) for men with cancer that has spread to the bone
  • Docetaxel (Docefrez, Taxotere) and prednisone
  • Sipuleucel-T (Provenge) for men who have few or no symptoms from the cancer
  • Cabazitaxel (Jevtana) and prednisone for men with prostate cancer that has worsened while receiving docetaxel

The following treatments could be options, as well. However, the research has not yet shown that they lengthen men’s lives:

  • Mitoxantrone (Novantrone) plus prednisone
  • Bicalutamide (Casodex), flutamide (Eulexin), nilutamide (Nilandron), which are all types of anti-androgens
  • Ketoconazole (Nizoral, Xolegel)
  • Low-dose corticosteroids

The following treatments are not recommended:

  • Bevacizumab (Avastin)
  • Estramustine (Emcyt)
  • Sunitinib (Sutent)

What This Means for Patients

A diagnosis of metastatic castration-resistant prostate cancer often means that treatments to slow, stop, or eliminate the cancer are no longer working by themselves. This diagnosis is stressful, and it may be difficult to discuss with your health care team. There are several promising treatments available, each of which affects a man’s life differently. Because of the variety of treatment options, men should talk with their doctor about the different treatment options for castration-resistant prostate cancer, including the overall goals of treatment, possible benefits, the risks, and the costs. Before considering additional treatments, it is important to have open and honest conversations with your doctor and health care team to express your feelings, preferences, and concerns.

Questions to Ask the Doctor

Consider asking the following questions of your doctor:

  • What type of prostate cancer do I have? What does this mean?
  • What is my prognosis (chance of recovery)?
  • What clinical trials are open to me?
  • What treatment plan do you recommend? Why?
  • What is the goal of each treatment? Is it to eliminate the cancer, help me feel better, or both?
  • How well is this treatment likely to work? What are the risks?
  • How will we know the treatment is working?
  • How will my quality of life change over time?
  • What are the next steps if the cancer worsens or comes back?
  • What treatments are available to manage the symptoms of the cancer?
  • If I’m worried about managing the costs related to my cancer care, who can help me with these concerns?
  • Where can I find support for me and my family?
  • Whom should I call with questions or concerns?

Read the entire clinical practice guideline published at .

Statistics – Asbestos related lung cancer #statistics, #statistical, #data, #diseases, #asbestos, #asbestosis, #lung #cancer, #tobacco #smoke, #exposure, #mesothelioma, #deaths, #


Asbestos related lung cancer


  • The overall scale of asbestos-related lung cancer deaths has to be estimated rather than counted.
  • Research suggests there are currently about as many lung cancer deaths attributed to past asbestos exposure each year in Great Britain as there are mesothelioma deaths.
  • This implies there are currently in excess of 2,000 asbestos-related lung cancer deaths each year.
  • This estimate is uncertain, and since asbestos and smoking act together to increase the risk, it is affected by past smoking habits as well as asbestos exposure.

Background information

Asbestos is one of a large number of agents that can cause lung cancer, the most important of which is tobacco smoking.

Lung cancer usually has no specific clinical signs suggesting a particular cause and asbestos exposure and smoking act together to increase the risk. This – together with the fact that cases usually take many years to develop – makes it difficult to be sure about the cause of individual cases. As a consequence, data sources that rely on the counting of individual cases attributed to asbestos exposures, such as Industrial Injuries Disablement Benefit (IIDB) and the Health and Occupation Reporting (THOR) schemes, tend to underestimate the true scale of asbestos-related cases.

Epidemiological analyses that are representative of the British population suggest that there are likely to be about as many lung cancer cases attributed to past asbestos exposure each year in the population as a whole as there are mesotheliomas 1. 2. This implies there are currently in excess of 2000 asbestos-related lung cancer deaths each year.

This estimate is uncertain. Since asbestos and smoking act together to increase the risk of lung cancer, it is affected by past smoking habits as well as the extent of asbestos exposure. The ratio of lung cancers to mesotheliomas is expected to fall over time, a reflection of reductions in both asbestos exposure and the prevalence of smoking. Among more specific groups of workers heavily exposed to asbestos in the past there were typically a greater number of excess lung cancer cases than there were mesotheliomas 3.

Lung cancer is still typically fatal within a few years of diagnosis and so, as with the mesothelioma, the number of annual deaths is similar to the annual incidence of new cases.

In recent years there have been, on average, around 300 new cases of asbestos-related lung cancer each year within the IIDB scheme and less than 100 cases identified by chest physicians each year within the THOR scheme.

Estimates of the burden of lung cancer attributable to occupational exposures other than asbestos are available based on the Burden of Occupational Cancer research.


  1. Darnton A, McElvenny D, Hodgson J (2005). Estimating the number of asbestos related lung cancer deaths in Great Britain from 1980-2000. Annals of Occupational Hygiene 50(1): 29-38.
  2. Gilham C, Rake C, Burdett G et al (2015). Pleural mesothelioma and lung cancer risks in relation to occupational history and asbestos lung burden. Occup Environ Med. 73(5):290-9.
  3. McCormack V, Peto J, Byrnes G et al (2012). Estimating the asbestos-related lung cancer burden from mesothelioma mortality. Br J Cancer. 106(3):575-84.


Access: Clues to the functions of mammalian sleep: Nature #nature, #science, #science #news, #biology, #physics, #genetics, #astronomy, #astrophysics, #quantum #physics, #evolution, #evolutionary #biology, #geophysics, #climate #change, #earth #science, #materials #science, #interdisciplinary #science, #science #policy, #medicine, #systems #biology, #genomics, #transcriptomics, #palaeobiology, #ecology, #molecular #biology, #cancer, #immunology, #pharmacology, #development, #developmental #biology, #structural #biology, #biochemistry, #bioinformatics, #computational #biology, #nanotechnology, #proteomics, #metabolomics, #biotechnology, #drug #discovery, #environmental #science, #life, #marine #biology, #medical #research, #neuroscience, #neurobiology, #functional #genomics, #molecular #interactions, #rna, #dna, #cell #cycle, #signal #transduction, #cell #signalling




Article Links

Article Tools

Search Pubmed for

Review Article Clues to the functions of mammalian sleep

Jerome M. Siegel 1


The functions of mammalian sleep remain unclear. Most theories suggest a role for non-rapid eye movement (NREM) sleep in energy conservation and in nervous system recuperation. Theories of REM sleep have suggested a role for this state in periodic brain activation during sleep, in localized recuperative processes and in emotional regulation. Across mammals, the amount and nature of sleep are correlated with age, body size and ecological variables, such as whether the animals live in a terrestrial or an aquatic environment, their diet and the safety of their sleeping site. Sleep may be an efficient time for the completion of a number of functions, but variations in sleep expression indicate that these functions may differ across species.

To read this story in full you will need to login or make a payment (see right).


These links to content published by NPG are automatically generated.


Nature Medicine News and Views (01 May 2000)

Nature Neuroscience News and Views (01 Oct 2003)

I want to purchase this article

In order to purchase this article you must be a registered user.

I want to subscribe to Nature

This includes a free subscription to Nature News together with Nature Journal.

I want to rent this article

Personal subscribers to Nature can view articles published from 1997 to the current issue. To do this, associate your subscription with your registration via the My Account page. If you already have an active subscription, login here to your account. View our privacy policy and use of cookies .

If you do not have access to the article you require, you can purchase the article (see below) or access it through a site license. A site license includes a minimum of four years of archived content ; institutions can add additional archived content to their license at any time. Recommend site license access to your institution.

You can request this document from a number of document delivery services

You can also request this document from your local library through inter library loan services.

Lung-Sparing Surgery May Up Mesothelioma Survival #mesothelioma, #mesothelioma #treatment, #surgery, #lung, #lung #cancer, #mesothelioma #surgery, #asbestos


Lung-Sparing Surgery May Up Mesothelioma Survival

By Maureen Salamon

FRIDAY, Dec. 23, 2016 (HealthDay News) — Surgery that preserves the lung. when combined with other therapies, appears to extend the lives of people with a subtype of the rare and deadly cancer mesothelioma. a new study suggests.

Tracking 73 patients with advanced malignant pleural mesothelioma — which affects the lungs’ protective lining in the chest cavity — researchers found that those treated with lung-sparing surgery had an average survival of nearly three years. A subset of those patients survived longer than seven years.

Mesothelioma patients treated with chemotherapy alone, which is standard care, live an average of 12 to 18 months, the researchers said.

Study participants received lung-sparing surgeries and another treatment called photodynamic therapy that uses light to kill cancer cells. Ninety-two percent of the group also received chemotherapy.

The study volunteers achieved far longer survival times, said study author Dr. Joseph Friedberg.

“When you take the [entire] lung out, it’s a significant compromise in quality of life,” said Friedberg. He’s director of the University of Maryland Medical Center’s Mesothelioma and Thoracic Oncology Treatment and Research Center in Baltimore.

“For all intents and purposes, this [lung-sparing surgical approach] is the largest palliative operation known to man, since chances of curing mesothelioma are vanishingly small,” said Friedberg. He completed the research while at his previous post at the University of Pennsylvania.

“Plus, most of these patients are elderly, so preserving quality of life was really the goal,” he added.

About 3,000 Americans are diagnosed with mesothelioma each year, the American Cancer Society says. Many of these people were exposed to the mineral asbestos in industrial occupations, according to the U.S. National Cancer Institute (NCI).

Used in products such as insulation, building shingles and flooring, asbestos dust fibers can be inhaled or swallowed, settling in the lungs, stomach or other body areas. Often, it takes decades after exposure for mesothelioma to develop, the NCI says.

Friedberg and his team performed the lung-sparing surgeries on study participants between 2005 and 2013. Overall average survival was 35 months, the study showed. But survival time more than doubled to 7.3 years for 19 patients whose cancer had not spread to their lymph nodes.


Most of the patients in the study had stage 3 or stage 4 cancer. Typically, Friedberg said, only about 15 to 20 percent of mesothelioma patients are treated with surgery, which often removes an entire lung as well as the diaphragm and the sac surrounding the heart .

Friedberg said that between 20 and 40 percent of pleural mesothelioma patients with the epithelial subtype might be eligible for lung-sparing surgery. He explained that this surgery removes all visible traces of cancer. It typically has fewer complications and a lower risk of dying in the 90 days following the 10- to 14-hour procedure.

“It’s still relatively new that people do lung-sparing surgery for this disease, and it’s not established that this is what we need to do,” said Friedberg.

“I would say this is one of the most lethal cancers known to man. There’s a pressing need for new and innovative treatments,” he noted.

Another mesothelioma expert said he was cautiously optimistic about the new study’s results.

“It’s not a randomized trial and I think they selected out. only those patients who were well enough to get to surgery and those with the epithelial subtype who are the patients who tend to do the best,” said Dr. Gregory Masters.

He is principal investigator with the U.S. National Cancer Institute Community Oncology Research Program at the Helen F. Graham Cancer Center and Research Institute in Newark, Del.

“Taking the best patients is going to skew the study and make the outcome look very good,” added Masters. “But I am encouraged they can take a large group of patients and show such a good outcome at three years.”

Dr. Daniel Petro, a medical oncologist/hematologist at the University of Pittsburgh Medical Center, said lung-sparing surgery for mesothelioma is also done at academic centers such as his, and he was not surprised by the study’s results.

“This [surgical approach] is a step forward with this particular terrible cancer,” Petro said, “and we’ve got to keep coming up with better options to eradicate it.”

The study was published in the December issue of Annals of Thoracic Surgery.

WebMD News from HealthDay


SOURCES: Joseph S. Friedberg, M.D. director, Mesothelioma and Thoracic Oncology Treatment and Research Center, University of Maryland Medical Center, and professor, surgery, and head, Division of Thoracic Surgery, University of Maryland School of Medicine, Baltimore; Gregory A. Masters, M.D. principal investigator, U.S. National Cancer Institute Community Oncology Research Program (NCORP), Helen F. Graham Cancer Center and Research Institute, Christiana Care Health System, Newark, Del.; Daniel Petro, M.D. medical oncologist/hematologist, Hillman Cancer Center, University of Pittsburgh Medical Center; December 2016, Annals of Thoracic Surgery

Top Picks

How your donations help – Canadian Cancer Society #cancer #society #car #donation


How your donations help

Your support means the world to us. Every dollar counts in our efforts to reduce the burden of cancer on Canadians. Thanks to your donations, we re able to continue funding the most promising cancer research, advocate for health-protecting policies and provide trusted information, resources and support for every Canadian who is on a cancer journey. Thank you!

You fund Canada s best cancer research

Thanks to Canadians like you, the Society has channeled over $1.3 billion to cancer research since the 1940s. In that time, Canadians 5-year survival rate has increased from 25% to more than 60%.

In 2015, you enabled us to invest $44 million in Canada s most promising cancer research. Together, we supported 297 lead investigators and a total of 357 research projects and awards.

The Society funds research into all types of cancer, across the spectrum of prevention and risk, diagnostic tools, treatment, survivorship and palliative care. Read about the impact of your donations to research.

You help people living with cancer and their caregivers

Your donations have made the Society the most trusted source of information and support for Canadians. In 2014, we dedicated $69 million to this area of our work.

More than 5,100 Canadians got the support they needed through our telephone-based peer support program

Our online community grew to more than 46,000 members who supported each other through forums, blogs and sharing experiences

Cancer – Life Insurance #term #life #insurance #for #cancer #patients



How Cancer Patients Survivors Can Obtain Coverage

Many cancer patients, and even survivors, may believe that they will not be able to find life insurance coverage, at least at an affordable rate. While it is true that some providers will deny coverage for certain health conditions, you still have options when searching for insurance with a cancer diagnosis.

With almost a million Americans diagnosed every year with some form of cancer, more and more options are available for term life insurance. Term Life Insurance can help you get quotes from multiple providers, and choose the plan that fits your needs best. Let’s explore some of the factors that may impact your insurance options.

How A Cancer Diagnosis Affects Eligibility

Your ability to obtain coverage following a cancer diagnosis will depend on a number of factors, including the type of cancer, and whether you are currently undergoing treatment or if your cancer is in remission. Unfortunately, if you are still in treatment, you may be limited in terms of insurance availability. In this case your best option may be high risk or guaranteed acceptance plans, which offer limited benefits and usually higher out of pocket costs.

If, however, you are cancer free, you are only a matter of time away from affordable coverage. Each type of cancer has its own waiting period depending on severity and likelihood of recurrence. Waiting until after you have completed treatment and you waiting period has passed will give you the best chance of being approved for coverage.

Waiting Periods For Cancer Policies

Each provider may set their own specific requirements for any condition, but this guide will share some of the most common waiting periods.

  • Leukemia has the longest at 10 years.
  • Bone and Metastatic Cancer typically require 5 years.
  • Esophageal, Kidney, Lung, and Ovarian Cancer usually call for 3 years.
  • Bladder, Breast, Colon, Lymphoma, Pancreatic, Rectum, and Salivary Cancers require 2 years.
  • Cervical, Larynx, Prostate, Skin, and Testicular Cancers typically require 1 year.

Special Cases For Cancer Patients

With some forms of cancer, companies will examine certain aspects of your condition more carefully. Since each type of cancer requires different treatment, and has different effects on the body, insurance providers view them differently in terms of risk as well.

Breast Cancer

Approval for life insurance after breast cancer depends heavily on the length of time that you have been cancer free. The more often you are screened for recurrence, combined with the type of treatment you received and the number of years you have spent symptom free all contribute to your ability to obtain coverage.

Prostate Cancer

For prostate cancer patients, along with the length of time you have spent cancer free, two other factors may impact your acceptance. Your Gleason score, which estimates the chances that your cancer will spread to other parts of the body, can improve your options if the value is low. Your PSA levels, or prostate specific antigens, will also be examined.


As the most serious of skin cancers, melanoma commonly spreads and can often metastasize, making it a high-risk health condition. If your cancer has been surgically removed, and does not spread to other areas, you have the best chance of approval. If the cancer has spread, and you have received treatment for other areas, you may be required to wait an extended period of time before being approved, and premiums could still be much higher.

Skin Cancer (Non-Melanoma)

Squamous and Basal Cell Carcinomas are by far the most common types of skin cancer. Because of the slow movement and relatively easy removal, your approval is much more likely, especially after a year or two being cancer free.

Discover Your Options After Cancer

If you’re looking for life insurance coverage after a cancer diagnosis, get started with a quote through Term Life Insurance. We can help you find all your options, and choose a provider and a plan that fits your needs and budget.

Lee Haskins and James DeGale lead appeal for Bristol boxing legend Dean Francis following cancer diagnosis – Mirror Online #james #degale,commonwealth,world #champions,cancer


Lee Haskins and James DeGale lead appeal for Bristol boxing legend Dean Francis following cancer diagnosis

Olympic and world champion James DeGale has thrown his support behind a campaign to raise funds for Bristol boxer Dean Francis who has been diagnosed with terminal cancer.

Francis had a 20-year career which saw him win British, European, Inter-Continental and Commonwealth titles under the nickname ‘Star’.

The 43-year-old retired three years ago and last week tragically received the news that he was suffering from incurable cancer.

Fellow Bristolian fighter Lee Haskins has set up a fundraising page as he looks to raise 100,000 for his friend Francis and his family to battle the illness and research a cure.

DeGale posted a link to the page on Twitter urging his followers to spare any money they can.

Sad news! Please donate every penny counts, he wrote on the social media page.

Haskins also paid tribute to Francis’ role in the Bristol comminuty.

Dean trains and mentors people like myself and inspiring boxers and youngsters within the community, he said.

He has found happiness and is very much a family man and well loved by many close friends.

Francis won a host of title during a 20-year career (Photo: Reading Post)

Dean also supports his wife in her business little star workshops’ in their hometown Chepstow. An independent, thriving child’s workshop and cafe located in the town centre which has been open less than a year, an adventure the newly married embarked on, inspired by their special little boy, he added.

Cancer doesn’t stop for anyone, he wrote. It doesn’t matter who you are, your age, or however physically fit and emotionally strong you are, but when it hits you, your family and friends, everyday reality and routine as you know it, all you want to do is fight back.

Last week Dean had been told that his cancer is treatable and curable. Today this has taken a turn for the worst and has been told it’s now so aggressive it’s incurable.

Francis’ friends are looking to raise funds for his family (Photo: The People)

We would like you to help us raise funds to help Dean prolong his life by funding alternative cancer treatments.

Having always been a fighter, Dean has overcome the impossible in his boxing career after a shoulder injury that told him he can never box again. Against all the odds he fought his way to the top again.

We need your kindness and support to help Dean and his family a chance to fight this illness that destroys so many lives.

Greg Lake dead aged 69: Lead singer of King Crimson and Emerson loses battle with cancer – Mirror Online #greg #lake,keith #emerson,cancer


Greg Lake dead aged 69: Lead singer of King Crimson and Emerson loses battle with cancer

Greg Lake, Keith Emerson and Carl Palmer at Kennington Oval with their awards gained in the Melody Maker Polls (Photo: PA)

Celebrated British singer, musician, songwriter and producer Greg Lake has passed away after a long and hard fought battle with cancer.

The Dorset born vocalist, who fronted both King Crimson and Emerson, Lake and Palmer, has died at the age of 69.

Greg was one of the founding fathers of progressive rock, and amongst his many musical accomplishments he’s best remembered for songs including In the Court of the Crimson King and 21st Century Schizoid Man.

Greg Lake, Keith Emerson and Carl Palmer at Kennington Oval with their awards gained in the Melody Maker Polls (Photo: PA)

Greg Lake has passed away after a battle with cancer (Photo: Getty)

He also recorded as a solo artist, most notably scoring a major hit single in 1975 with I Believe in Father Christmas.

His manager confirmed that he passed away on Tuesday after a long and stubborn battle with cancer , said his manager.

A full statement on Greg’s Facebook page reads: Yesterday, December 7th, I lost my best friend to a long and stubborn battle with cancer.

Greg Lake will stay in my heart forever, as he has always been. His family would be grateful for privacy during this time of their grief. Many thanks, Stewart Young.

Yes keyboardist Geoff Downes also reacted to the news, saying: “Very sad about Greg Lake. I had the privilege of working with him on several projects. His great talent will be sorely missed by all.

Another genius has passed away. 2016 has truly been an annus horribilis in musical history.

Keyboard player Rick Wakeman also added: Another sad loss with the passing of Greg Lake. You left some great music with us my friend so like Keith. you will live on.

Greg was a fan of all music and expressed this through the many tracks he made himself.

On his website he wrote: There is a common thread throughout all the music. The forms may be different, but each one to some degree draws upon inspiration from the past.

I am as proud to have been as influenced by people like Elvis and Little Richard as I am by composers like Copeland and Prokofiev and I’m honoured when other musicians regard me as one of their inspirations.

The news comes nine months after Lake’s band-mate Keith Emerson also died.

Keyboardist Emerson died of a self-inflicted gunshot wound, coroners in the US said.